Jul 15, 2025 10:33AM H.C. Wainwright Downgrades MiNK Therapeutics (INKT) to Neutral

Jul 15, 2025 08:27AM MiNK Therapeutics publishes research on iNKT cell therapy platform

Jul 14, 2025 07:22AM William Blair Downgrades MiNK Therapeutics (INKT) to Market Perform

Jul 14, 2025 07:08AM H.C. Wainwright Reiterates Buy Rating on MiNK Therapeutics (INKT)

Jul 11, 2025 10:46AM Agenus (AGEN) Trades Higher in Sympathy with MiNK Therapeutics (INKT)

Jul 11, 2025 07:30AM MiNK Therapeutics reports complete remission in testicular cancer patient

Jun 2, 2025 09:29AM MiNK Therapeutics (INKT) Awarded NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025 04:43PM MiNK Therapeutics, Inc. (INKT) Misses Q1 EPS by 64c

Mar 18, 2025 04:05PM MiNK Therapeutics, Inc. (INKT) Misses Q4 EPS by 54c

Feb 25, 2025 06:44AM MiNK Therapeutics (INKT) PT Raised to $35 at H.C. Wainwright

Feb 20, 2025 07:30AM MiNK Therapeutics (INKT) Regains Nasdaq Compliance

Feb 12, 2025 01:03PM MiNK Therapeutics (INKT) to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025 02:13PM MiNK Therapeutics (INKT) Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Nov 15, 2024 07:21AM MiNK Therapeutics (INKT) PT Lowered to $4 at Baird

Oct 18, 2024 04:12PM MiNK Therapeutics (INKT) Announces Transition of Chief Scientific Officer

Oct 9, 2024 06:56AM H.C. Wainwright Reiterates Buy Rating on MiNK Therapeutics (INKT)

Aug 13, 2024 04:37PM MiNK Therapeutics (INKT) Files for 4.64M Share Offering by Selling Stockholders

Aug 13, 2024 07:06AM MiNK Therapeutics, Inc. (INKT) Tops Q2 EPS by 3c

Jul 31, 2024 07:31AM MiNK Therapeutics (INKT) Regains Nasdaq Compliance